Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43409 ↗Kurz gefasst
Fallbericht in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Alvise Berti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Rheumatology, S. Chiara Hospital, ASUIT, Trento, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Churg-Strauss Syndrome, Eosinophils, Interleukin-5. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient. We discuss available evidence proving the association between IL‐5 and clinical activity in EGPA and review the clinical efficacy and safety of currently approved IL‐5 pathway inhibitors (i.e. mepolizumab and benralizumab) that improve disease control, reduce relapse rates, and have significant glucocorticoid‐sparing effects in EGPA by reducing eosinophilic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Rheumatology, S. Chiara Hospital, ASUIT, Trento, Italy.
- Center for Medical Sciences (CISMed), University of Trento, Trento, Italy.
- Department of Cellular, Computational and Integrative Biology (dCIBIO), University of Trento, Trento, Italy.
- Vasculitis Clinic, Division of Rheumatology, Mount Sinai Hospital, University Health Network, Toronto, Ontario, Canada.
- Canadian Vasculitis Research Network, Toronto, Ontario, Canada.
Zitieren
APA
Berti, A., & Pagnoux, C. (2026). Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. https://doi.org/10.1002/art.43409
Vancouver
Berti A, Pagnoux C. Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 2026. doi:10.1002/art.43409
BibTeX
@article{Berti2026,
author = {Berti, Alvise and Pagnoux, Christian},
title = {Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43409}
}
EUVIMED